Robert J. Gil1,2, MD, PhD; Jacek Bil1, MD, PhD; Adam Kern3, MD, PhD; Luis A. Ingio Garcia4, MD; Radoslaw Formuszewicz5, MD; Slawomir Dobrzycki6, MD, PhD; Dobrin Vassilev7, MD, PhD; Agnieszka Segiet8, MSc, PhD
1. Department of Invasive Cardiology, Centre of Postgraduate Medical Education, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland; 2. Mossakowski Medical Research Center, Polish Academy of Science, Warsaw, Poland; 3. Department of Cardiology and Cardiosurgery, University of Warmia and Masury, Olsztyn, Poland; 4. Costa del Sol Hospital, Marbella, Spain; 5. 10th Clinical Military Hospital, Bydgoszcz, Poland; 6. Department of Invasive Cardiology, Medical University in Bialystok, Bialystok, Poland; 7. Alexandrovska University Hospital, Sofia, Bulgaria; 8. Warsaw Medical University, Warsaw, Poland
The wide variation in bifurcation anatomy has generated ongoing research for stents designed specifically for coronary bifurcations; results to date have been unsatisfactory1,2. Earlier, we presented 12 months of pooled data from the POLBOS I and II trials (ClinicalTrials.gov Identifiers: NCT02192840, NCT02198300)3; the present study extends the follow-up to four years.
The primary endpoint was the cumulative rate of major adverse cardiovascular events (MACE) consisting of cardiac death, myocardial infarction (MI), and target lesion revascularisation (TLR) within 48 months. The secondary endpoints were defined in the primary publication3.
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
Coronary interventionsLeft main and multivessel diseaseBifurcation lesions
Read next article
Percutaneous reintervention on aortic coarctation stenting